Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pfizer Announces 2 Percent Jobs Cuts Worldwide

Citing structural simplification, Pfizer announced plans to cut the company’s global staffing by about 2 percent, primarily through voluntary layoffs and early retirement through the end of 2018 and early in 2019.

Read More »

Bayer Cutting More Than 200 Jobs in San Francisco Bay Area

German company Bayer AG is laying off 227 staffers at the company’s manufacturing plant in Berkeley, California. Most of the cuts took place on October 3, 2018.

Read More »

Momenta Slashes Workforce and Leadership Following Strategic Review

Despite winning regulatory approval for a copycat version of Copaxone earlier in 2018, Cambridge, Mass.-based Momenta Pharmaceuticals completed a strategic review that includes slashing staff by 50 percent as the company focuses resources on two biosimilar candidates in the pipeline.

Read More »

Novo Nordisk to cut 250 jobs in the United States

Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.

Read More »

Novartis to cut 2,550 jobs in Switzerland, UK

Novartis will cut 2,550 jobs in Switzerland and Britain over four years as the Swiss drugmaker strives to boost profits and focus on new medicines.

Read More »

Novo Nordisk lays off 400 staff in R&D unit

Novo Nordisk said the world’s top maker of diabetes drugs will lay off 400 staff in Denmark and China as part of a broader restructuring of the company’s research and development organization.

Read More »

Realm Therapeutics Slashes Staff and Explores Potential Sale as the Company Conducts a Strategic Review

Realm Therapeutics opted to discontinue all drug development programs and is considering a potential sale of the Malvern, Pa.-based company following a clinical trial failure with the atopic dermatitis treatment PR022.

Read More »

Takeda to Move U.S. Headquarters to Boston Area

Takeda Pharmaceutical will shutter the company’s Deerfield, Ill., U.S. headquarters and move the operations to Boston as the company consolidates operations following the $62 billion acquisition of Shire. The Illinois facility employs about 1,000 people.

Read More »

Akcea Therapeutics to cut about 10 percent of workforce

Akcea Therapeutics Inc. planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve the company’s Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

Read More »

As Part of Global Restructuring, GlaxoSmithKline Pink-Slips 650 in the U.S.

As part of an earlier announced restructuring program, UK-based GlaxoSmithKline is laying off 650 staffers in the U.S.

Read More »

Novartis to Drop Anti-Infectives Research Programs

The Novartis Institutes for BioMedical Research is ending its early-stage anti-infectives research programs located in Emeryville, Calif. As a result, the company expects to lay off about 140 employees.

Read More »

Regulus Therapeutics Slashes 60 Percent of Workforce

Regulus Therapeutics announced a corporate restructuring that included the termination of 60 percent of the company’s workforce, which caused a massive stock plummet.

Read More »

OxyContin Maker Purdue Pharma to Cut 350 More Jobs

Purdue Pharma, which sells the painkiller OxyContin, announced that the company laid off approximately 350 staffers.

Read More »

Intarcia Pink Slips 60 Employees, Ends Studies

Boston-based Intarcia Therapeutics undertook a restructuring that includes the termination of up to 60 employees and the closing of two programs.

Read More »

Pernix Cuts 22 Percent of Workforce in Reorganization

Pernix Therapeutics is undergoing a reorganization that includes the termination of a number of sales representatives.

Read More »

Allergan to Slash 1,000+ Jobs

Allergan will cut 1,000 positions, about 5 percent of its workforce, as the company looks to cut costs.

Read More »

Teva Cuts 14,000 Jobs in Massive Reorganization

Teva Pharmaceutical announced a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.

Read More »

Depomed Pink Slips 40 Percent of Staff

Depomed Inc. is looking to relocate its headquarters from the Bay Area after inking a deal with Collegium Pharmaceutical Inc.

Read More »

Troubled Otonomy Cuts Jobs

Otonomy, which develops innovative therapeutics for diseases and disorders of the ear, is initiating more job cuts as well as planning to divest one of its assets.

Read More »

Mylan Chops Another 200 to 300 Jobs

Mylan reportedly let go between 200 and 300 people from its West Virginia operations.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom